Company research
Niagen Bioscience, Inc.
CIK 1386570Updated Nov 6, 2026
SecurityNAGE · NASDAQ · equity
Historical securities (1)
CDXC · OTC · equity · closed Apr 13, 2016Name history
ChromaDex Corp. · through Mar 10, 2025CODY RESOURCES, INC. · through Jun 24, 2008
NAGE price & chart
Loading TradingView…
NASDAQ:NAGE on TradingView ↗About the company
Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
In the news
No coverage from other publishers is available.
Seeking Alpha
Niagen Bioscience GAAP EPS of -$0.01 misses by $0.01, revenue of $27.2M misses by $4.7M ↗
Niagen Bioscience: Down 68%, But Still Not Quite A Buy ↗
SEC disclosures
Niagen Bioscience, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
424B5 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 98,139,000Source | 56,522,000Source | 106,589,000Source | 91,525,000Source | 54,035,000Source | 114,329,000Source | 81,337,000Source | 54,079,000Source | 106,406,000Source | 68,278,000Source | 54,964,000Source | 54,057,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 246,000Source | 397,000Source | 5,311,000Source | 284,000Source | 435,000Source | 5,485,000Source | 322,000Source | 472,000Source | 5,660,000Source | 359,000Source | 510,000Source | 671,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 64,100,000Source | 32,200,000Source | — | 60,300,000Source | 27,700,000Source | — | 55,500,000Source | 27,400,000Source | — | 44,500,000Source | 27,200,000Source | 20,300,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 8,506,000Source | 7,096,000Source | 8,580,000Source | 9,656,000Source | 7,818,000Source | 13,068,000Source | 7,052,000Source | 6,604,000Source | 9,741,000Source | — | — | 8,482,000Source |
| Inventory, NetUSD | 18,791,000Source | 10,544,000Source | 20,640,000Source | 14,406,000Source | 11,511,000Source | 24,016,000Source | 11,185,000Source | 12,495,000Source | — | 9,192,000Source | 14,525,000Source | 14,677,000Source |
| Assets, CurrentUSD | 93,616,000Source | 52,134,000Source | 97,786,000Source | 86,679,000Source | 49,302,000Source | 105,121,000Source | 76,218,000Source | 48,976,000Source | 96,806,000Source | 64,102,000Source | 49,534,000Source | 46,567,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,361,000Source | 1,899,000Source | 1,840,000Source | 2,525,000Source | 2,063,000Source | 2,019,000Source | 2,684,000Source | 2,226,000Source | 2,192,000Source | 1,730,000Source | 2,400,000Source | 3,523,000Source |
| Other Assets, NoncurrentUSD | 417,000Source | 374,000Source | 405,000Source | 405,000Source | 394,000Source | 406,000Source | 458,000Source | 405,000Source | 425,000Source | 368,000Source | 383,000Source | 497,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 27,463,000Source | 22,153,000Source | 24,061,000Source | 27,330,000Source | 23,317,000Source | 31,999,000Source | 25,992,000Source | 25,128,000Source | 29,873,000Source | 22,184,000Source | 26,508,000Source | 25,385,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 79,000Source | 76,000Source | 79,000Source | 79,000Source | 75,000Source | 79,000Source | 78,000Source | 75,000Source | 79,000Source | 77,000Source | 75,000Source | 74,000Source |
| Additional Paid in CapitalUSD | 239,266,000Source | 223,389,000Source | 239,698,000Source | 237,358,000Source | 221,612,000Source | 240,464,000Source | 232,119,000Source | 219,829,000Source | 240,991,000Source | 227,931,000Source | 218,845,000Source | 214,094,000Source |
| Retained Earnings (Accumulated Deficit)USD | -168,660,000Source | -189,089,000Source | -157,247,000Source | -173,238,000Source | -190,967,000Source | -158,210,000Source | -176,847,000Source | -190,952,000Source | -164,528,000Source | -181,910,000Source | -190,460,000Source | -185,493,000Source |
| Stockholders' Equity Attributable to ParentUSD | 70,676,000Source | 34,369,000Source | 82,528,000Source | 64,195,000Source | 30,718,000Source | 82,330,000Source | 55,345,000Source | 28,951,000Source | 76,533,000Source | 46,094,000Source | 28,456,000Source | 28,672,000Source |
| Liabilities and EquityUSD | 98,139,000Source | 56,522,000Source | 106,589,000Source | 91,525,000Source | 54,035,000Source | 114,329,000Source | 81,337,000Source | 54,079,000Source | 106,406,000Source | 68,278,000Source | 54,964,000Source | 54,057,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 22,712,000Source | 17,699,000Source | 15,050,000Source | 22,327,000Source | 17,867,000Source | 22,824,000Source | 20,837,000Source | 19,452,000Source | 19,919,000Source | 17,948,000Source | 20,622,000Source | 17,869,000Source |
| Operating Lease, Liability, CurrentUSD | 976,000Source | 1,008,000Source | 917,000Source | 957,000Source | 973,000Source | 1,032,000Source | 939,000Source | 850,000Source | 1,002,000Source | 982,000Source | 691,000Source | 680,000Source |
| Accounts Payable, CurrentUSD | 12,742,000Source | 6,903,000Source | 9,439,000Source | 13,680,000Source | 8,105,000Source | 13,277,000Source | 10,632,000Source | 7,899,000Source | 10,796,000Source | 8,526,000Source | 10,232,000Source | 9,679,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,077,000Source | 1,873,000Source | 1,412,000Source | 2,329,000Source | 2,133,000Source | 1,544,000Source | 2,576,000Source | 2,356,000Source | 1,815,000Source | 1,657,000Source | 2,563,000Source | 3,539,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,700,000Source | 9,592,000Source | 3,841,000Source | 7,381,000Source | 8,621,000Source | 7,621,000Source | 9,050,000Source | 10,465,000Source | 7,722,000Source | 7,817,000Source | 9,493,000Source | 7,337,000Source |
| Prepaid Expense and Other Assets, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 1,756,000Source | 735,000Source | 1,723,000Source | 1,488,000Source | 1,716,000Source | 1,075,000Source | 6,067,000Source | 3,656,000Source | 4,751,000Source | 5,739,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 3,573,000Source | 1,993,000Source | 11,635,000Source | -5,333,000Source | -152,000Source | 1,076,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,481,000Source | 2,106,000Source | 2,270,000Source | -1,067,000Source | 553,000Source | -744,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -1,194,000Source | 7,883,000Source | 13,504,000Source | 12,109,000Source | 7,117,000Source | -15,098,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 5,245,000Source | -32,000Source | -292,000Source | -143,000Source | -143,000Source | -334,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 2,354,000Source | 0Source | 251,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -2,290,000Source | 3,105,000Source | 6,916,000Source | 5,369,000Source | -90,000Source | 7,654,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,761,000Source | 10,956,000Source | 20,128,000Source | 17,335,000Source | 6,884,000Source | -7,778,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 64,290,000Source | 32,398,000Source | 66,740,000Source | 60,474,000Source | 66,549,000Source | 55,616,000Source | 64,788,000Source | 44,660,000Source | 27,325,000Source | 20,441,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 1,000Source | 1,000Source | 2,000Source | 1,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 175,000Source | 37,000Source | 173,000Source | 151,000Source | 158,000Source | 186,000Source |
| DepreciationUSD | — | — | — | — | — | — | 116,000Source | 158,000Source | 612,000Source | 663,000Source | 870,000Source | 869,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 117,000Source | — | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | 0Source | -4,000Source | -4,000Source | 19,000Source | 5,000Source | -7,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 7,129,000Source | 6,304,000Source | 6,971,000Source | 7,267,000Source | 7,244,000Source | 5,184,000Source | 27,057,000Source | 18,375,000Source | 24,983,000Source | 28,286,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | 0Source | 3,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 222,000Source | 0Source | 106,000Source | 128,000Source | 417,000Source | 168,000Source | 810,000Source | 305,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 2,127,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 4,578,000Source | 1,878,000Source | 963,000Source | 3,609,000Source | 6,318,000Source | 5,063,000Source | 17,382,000Source | 8,550,000Source | -4,938,000Source | -16,540,000Source |
| Operating ExpensesUSD | — | — | 17,692,000Source | 14,638,000Source | 18,614,000Source | 17,041,000Source | 18,400,000Source | 14,559,000Source | 66,910,000Source | 53,860,000Source | 56,379,000Source | 61,425,000Source |
| Operating Lease, ExpenseUSD | — | — | 354,000Source | 326,000Source | 354,000Source | 318,000Source | 353,000Source | 320,000Source | 1,330,000Source | 1,314,000Source | 1,214,000Source | 1,281,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 7,747,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 111,000Source | 3,114,000Source | 7,246,000Source | 5,432,000Source | — | 0Source |
| Gain (Loss) on Disposition of Business | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 33,986,000Source | 25,580,000Source | 29,785,000Source | 31,117,000Source | 31,474,000Source | 30,481,000Source | 129,423,000Source | 99,597,000Source | 83,570,000Source | 72,050,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | 4,236,000Source | 1,602,000Source | 700,000Source | 3,185,000Source | 1,576,000Source | 4,772,000Source | 16,279,000Source | 7,726,000Source | -5,599,000Source | -18,628,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 4,800,000Source | 1,878,000Source | 1,069,000Source | 3,737,000Source | 6,735,000Source | 5,231,000Source | 18,192,000Source | 8,855,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | 222,000Source | 0Source | 106,000Source | 128,000Source | 417,000Source | 168,000Source | 810,000Source | 305,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 4,578,000Source | 1,878,000Source | 963,000Source | 3,609,000Source | 6,318,000Source | 5,063,000Source | 17,382,000Source | 8,550,000Source | -4,938,000Source | -16,540,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.06Source | 0.02Source | 0.01Source | 0.05Source | 0.08Source | 0.07Source | 0.22Source | 0.11Source | -0.07Source | -0.24Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.05Source | 0.02Source | 0.01Source | 0.04Source | 0.07Source | 0.06Source | 0.2Source | 0.11Source | -0.07Source | -0.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 79,779,000Source | 75,972,000Source | 79,322,000Source | 79,249,000Source | 79,917,000Source | 77,810,000Source | 79,178,000Source | 75,929,000Source | 74,985,000Source | 69,729,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 86,619,000Source | 77,768,000Source | 82,504,000Source | 86,241,000Source | 84,566,000Source | 83,232,000Source | 85,436,000Source | 78,125,000Source | 74,985,000Source | 69,729,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 175,000Source | 37,000Source | 173,000Source | 151,000Source | 158,000Source | 186,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 810,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | 2,000,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 7,129,000Source | 6,304,000Source | 6,971,000Source | 7,267,000Source | 7,244,000Source | 5,184,000Source | 27,057,000Source | 18,375,000Source | 24,983,000Source | 28,286,000Source |
| Gross ProfitUSD | — | — | 21,928,000Source | 16,240,000Source | 19,314,000Source | 20,226,000Source | 19,976,000Source | 19,331,000Source | 83,189,000Source | 61,586,000Source | 50,780,000Source | 42,797,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 18,218,000Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | 661,000Source | 3,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 564,000Source | 276,000Source | 372,000Source | 552,000Source | 375,000Source | 459,000Source | 1,913,000Source | 1,129,000Source | — | — |
| Investment Income, InterestUSD | — | — | — | — | — | — | — | — | 2,127,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 17,692,000Source | 14,638,000Source | 18,614,000Source | 17,041,000Source | 18,400,000Source | 14,559,000Source | 66,910,000Source | 53,860,000Source | 56,379,000Source | 61,425,000Source |
| Operating Lease, ExpenseUSD | — | — | 354,000Source | 326,000Source | 354,000Source | 318,000Source | 353,000Source | 320,000Source | 1,330,000Source | 1,314,000Source | 1,214,000Source | 1,281,000Source |
| Research and Development ExpenseUSD | — | — | 1,795,000Source | 1,290,000Source | 1,513,000Source | 1,567,000Source | 1,481,000Source | 1,258,000Source | 6,330,000Source | 6,016,000Source | 4,958,000Source | 4,826,000Source |
| Selling and Marketing ExpenseUSD | — | — | 8,768,000Source | 7,044,000Source | 10,130,000Source | 8,207,000Source | 9,675,000Source | 8,117,000Source | 35,506,000Source | 29,469,000Source | 26,438,000Source | 28,313,000Source |
| Selling ExpenseUSD | — | — | 2,905,000Source | 2,375,000Source | 3,072,000Source | 2,766,000Source | 2,865,000Source | 2,663,000Source | 11,257,000Source | 9,822,000Source | — | — |
Offerings
Registration 333-297093
Filing attachments
ea029479701ex4-4.htm · S-3 · 2026-06-29
Exhibit 4.4 NIAGEN BIOSCIENCE, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities Table of Contents Page Article 1 DEFINITIONS 1 Section 01. …
Read attachment ↗ea029479701ex4-7.htm · S-3 · 2026-06-29
Exhibit 4.7 Niagen Bioscience, Inc. and _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ Niagen Bioscience, Inc. Form of Common Stock Warrant Agreement This Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Niagen Bioscience, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as w…
Read attachment ↗ea029479701ex4-8.htm · S-3 · 2026-06-29
Exhibit 4.8 Niagen Bioscience, Inc. and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ Niagen Bioscience, Inc. Form of Debt Securities Warrant Agreement This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Niagen Bioscience, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in …
Read attachment ↗ex991-nagepressreleasexsha.htm · 8-K · 2026-03-19
EX-99.1 2 ex991-nagepressreleasexsha.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience Increases Share Repurchase Program to $20 Million LOS ANGELES - March 19, 2026 - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has authorized an increase to the Company’s previously disclosed share repurchase program (the “Program”), raising the total aut…
Read attachment ↗ex992-nageearningspresen.htm · 8-K · 2026-03-04
EX-99.2 3 ex992-nageearningspresen.htm EX-99.2 ex992-nageearningspresen Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026 2 This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-loo…
Read attachment ↗ex991-nagepressreleasexref.htm · 8-K · 2026-02-26
EX-99.1 2 ex991-nagepressreleasexref.htm EX-99.1 Document Exhibit 99.1 Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction Divestiture streamlines operations and advances the Company’s strategy to fully exit non-core activities LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today a…
Read attachment ↗